Fluorescent In Situ Hybridization in Surgical Pathology Practice

Adv Anat Pathol. 2018 Jul;25(4):223-237. doi: 10.1097/PAP.0000000000000194.

Abstract

There have been rapid and significant advances in diagnostic and predictive molecular techniques in recent years with profound impact on patient care. In situ hybridization (ISH) studies have become well entrenched in surgical pathology practice and their role in the evaluation of HER2 in breast carcinoma and their diagnostic utility in soft tissue pathology are well known. Fluorescent ISH is being increasingly used in other sites such as the head and neck and the gynecologic tract. Like most tests in surgical pathology, ISH studies require good quality tissue, correlation with clinical and histopathologic findings, and adherence to guidelines for optimal assay performance and interpretation. Although ISH studies are largely performed in tertiary centers, the tissue is often processed by a variety of laboratories and the referring pathologists are required to discuss the need, relevance, and significance of these tests and the results with their clinical colleagues. Here we review the predictive and diagnostic utility of fluorescent ISH studies in a variety of organ systems, the preanalytical factors that may affect the results, and the pitfalls in the interpretation that all practicing surgical pathologists should be aware of.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Humans
  • In Situ Hybridization, Fluorescence / methods*
  • Neoplasms / diagnosis*
  • Pathology, Surgical / methods*

Substances

  • Biomarkers, Tumor